Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MINNEAPOLIS, AUG. 14, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND OTHER RECENT BUSINESS DEVELOPMENTS.

CELCUITY INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MINNEAPOLIS, AUG. 07, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AFTER THE MARKET CLOSES ON THURSDAY, AUGUST 14, 2025. MANAGEMENT WILL HOST A WEBCAST/TELECONFERENCE THE SAME DAY AT 4:30 P.M. EASTERN TIME TO DISCUSS THE RESULTS AND PROVIDE A CORPORATE UPDATE.

CELCUITY INC. SCHEDULES RELEASE OF SECOND QUARTER 2025 FINANCIAL RESULTS AND WEBCAST/CONFERENCE CALL

MINNEAPOLIS, JULY 30, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC) (THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF $175,000,000 AGGREGATE PRINCIPAL AMOUNT OF ITS 2.750% CONVERTIBLE SENIOR NOTES DUE 2031 (THE CONVERTIBLE NOTES AND SUCH OFFERING, THE CONVERTIBLE NOTES OFFERING), AND ITS UNDERWRITTEN PUBLIC OFFERING OF 1,836,842 OF SHARES OF ITS COMMON STOCK (THE COMMON STOCK) AT A PUBLIC OFFERING PRICE OF $38.00 PER SHARE AND, IN LIEU OF COMMON STOCK TO INVESTORS WHO SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE UP TO 400,000 SHARES OF COMMON STOCK (THE PRE-FUNDED WARRANTS) AT A PUBLIC OFFERING PRICE OF $37.999 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE OF EACH PRE-FUNDED WARRANT (SUCH OFFERING, THE COMMON STOCK OFFERING).

CELCUITY INC. ANNOUNCES PRICING OF CONCURRENT PUBLIC OFFERINGS OF 2.750% CONVERTIBLE SENIOR NOTES DUE 2031 AND COMMON STOCK AND PRE-FUNDED WARRANTS

MINNEAPOLIS, JULY 28, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC) (THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED PROPOSED UNDERWRITTEN PUBLIC OFFERINGS OF $150,000,000 AGGREGATE PRINCIPAL AMOUNT OF ITS CONVERTIBLE SENIOR NOTES DUE 2031 (THE CONVERTIBLE NOTES AND SUCH OFFERING, THE CONVERTIBLE NOTES OFFERING) AND $75,000,000 OF SHARES OF ITS COMMON STOCK (THE COMMON STOCK AND, SUCH OFFERING, THE COMMON STOCK OFFERING).

CELCUITY INC. ANNOUNCES CONCURRENT PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES DUE 2031 AND COMMON STOCK

HAZARD RATIOS AND IMPROVEMENTS IN MEDIAN PFS ARE UNPRECEDENTED IN HR+/HER2- ADVANCED BREAST CANCER (ABC)

CELCUITY ANNOUNCES CLINICALLY MEANINGFUL IMPROVEMENT IN BOTH PROGRESSION-FREE SURVIVAL (PFS) PRIMARY ENDPOINTS FROM PIK3CA WILD-TYPE COHORT OF PHASE 3 VIKTORIA-1 TRIAL

MINNEAPOLIS, JULY 25, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED THE COMPANY WILL HOLD A CONFERENCE CALL AND WEBCAST ON MONDAY, JULY 28, 2025 AT 8:00 AM ET TO DISCLOSE THE TOPLINE RESULTS OF THE PIK3CA WILD-TYPE COHORT FROM THE PHASE 3 VIKTORIA-1 TRIAL.

CELCUITY TO ANNOUNCE TOPLINE RESULTS FOR THE PIK3CA WILD-TYPE COHORT FROM PHASE 3 VIKTORIA-1 TRIAL IN HR+/HER2- ADVANCED BREAST CANCER

MINNEAPOLIS, JULY 24, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN VIKTORIA-2, ITS PHASE 3 CLINICAL TRIAL EVALUATING GEDATOLISIB PLUS A CDK4/6 INHIBITOR AND FULVESTRANT AS FIRST-LINE TREATMENT FOR PATIENTS WITH HR+/HER2- ADVANCED BREAST CANCER (ABC) WHO ARE ENDOCRINE THERAPY RESISTANT. GEDATOLISIB IS AN INVESTIGATIONAL, MULTI-TARGET PI3K/AKT/MTOR (PAM) INHIBITOR THAT POTENTLY TARGETS ALL FOUR CLASS I PI3K ISOFORMS, MTORC1, AND MTORC2 TO INDUCE COMPREHENSIVE BLOCKADE OF THE PAM PATHWAY.

CELCUITY ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 VIKTORIA-2 CLINICAL TRIAL OF GEDATOLISIB AS A FIRST-LINE TREATMENT FOR HR+/HER2- ADVANCED BREAST CANCER

MINNEAPOLIS, JULY 14, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED THE ISSUANCE OF U.S. PATENT NO. 12,350,276 COVERING THE CLINICAL DOSING REGIMEN FOR ITS LEAD DRUG CANDIDATE, GEDATOLISIB, IN ER+/HER2- BREAST CANCER PATIENTS. THE PATENT EXTENDS CELCUITY'S PATENT EXCLUSIVITY IN THE U.S. INTO 2042.

CELCUITY ANNOUNCES ISSUANCE OF NEW PATENT FOR GEDATOLISIB THAT EXTENDS PATENT EXCLUSIVITY INTO 2042

 IN THE PHASE 1 PORTION OF THE CELC-G-201 CLINICAL TRIAL EVALUATING GEDATOLISIB PLUSDAROLUTAMIDE IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC),THE SIX-MONTH RADIOGRAPHIC PROGRESSION FREE SURVIVAL (RPFS) RATE WAS 66%

CELCUITY REPORTS CLINICAL DATA FROM TWO EARLY PHASE STUDIES OF GEDATOLISIB

MINNEAPOLIS, MAY 21, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED THAT BRIAN SULLIVAN, CHIEF EXECUTIVE OFFICER, AND CO-FOUNDER OF CELCUITY, WILL PRESENT AND BE AVAILABLE FOR ONE-ON-ONE INVESTOR MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES:

CELCUITY TO PRESENT AT UPCOMING TD COWEN AND JEFFERIES INVESTOR CONFERENCES

THE PRIMARY COMPLETION DATE OF THE PIK3CA WILD-TYPE COHORT OF THE VIKTORIA-1 PHASE 3 TRIAL IS EXPECTED IN JUNE 2025 AND A TOPLINE DATA READOUT IS ANTICIPATED IN THE THIRD QUARTER OF 2025 ENROLLMENT IS ONGOING IN THE PIK3CA MUTANT COHORT OF THE VIKTORIA-1 PHASE 3 TRIAL AND A TOPLINE DATA READOUT IS ANTICIPATED IN THE FOURTH QUARTER OF 2025 VIKTORIA-2 PHASE 3 TRIAL REMAINS ON TRACK TO DOSE ITS FIRST PATIENT IN THE SECOND QUARTER OF 2025 INITIATING A CLINICAL TRIAL COLLABORATION WITH THE DANA FARBER CANCER INSTITUTE AND MASSACHUSETTS GENERAL HOSPITAL TO EVALUATE GEDATOLISIB IN COMBINATION WITH ABEMACICLIB AND LETROZOLE IN PATIENTS WITH ENDOMETRIAL CANCER APPROXIMATELY $206 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AT MARCH 31, 2025 IS EXPECTED TO FUND CURRENT CLINICAL DEVELOPMENT PROGRAM ACTIVITIES THROUGH 2026 MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY, MAY 14, 2025, AT 4:30 P.M. ET MINNEAPOLIS, MAY 14, 2025 (GLOBE NEWSWIRE) -- CELCUITY INC. (NASDAQ: CELC), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PURSUING DEVELOPMENT OF TARGETED THERAPIES FOR ONCOLOGY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND OTHER RECENT BUSINESS DEVELOPMENTS.

Celcuity Inc.

CELC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Celcuity Inc.

CELC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CELC